Search results for " protocol"

showing 10 items of 1320 documents

A case of guillain-barre syndrome in a patient with non small cell lung cancer treated with chemotherapy

2006

Guillain-Barré Syndrome (GBS) is a demyelinating polyneuropathy of probable autoimmune pathogenesis characterized by rapidly progressive symmetric paralysis. In the literature some cases of GBS associated with anticancer chemotherapy are reported. We present a case of a 55-year old woman who complained of progressive motor deficit in four limbs, areflexia in lower limbs and facial nerve paralysis one week after beginning cisplatin-gemcitabine chemotherapy for metastatic lung cancer. The cerebrospinal fluid analysis showed a strong positive Pandy reaction with 435 mg/dl total protein. The electromyography and the electroneuronography established the diagnosis of inflammatory demyelinating po…

medicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentBone NeoplasmsGuillain-Barre SyndromeDeoxycytidineGastroenterologyPathogenesisCerebrospinal fluidCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsElectroneuronographyParalysismedicineHumansPharmacology (medical)Lung cancerPharmacologyChemotherapyGuillain-Barre syndromebusiness.industryGuillain-Barré Syndrome neuropathy chemotherapy toxicity lung cancerImmunoglobulins IntravenousMiddle Agedmedicine.diseaseGemcitabineFacial nerveSurgeryInfectious DiseasesOncologyFemaleCisplatinmedicine.symptombusiness
researchProduct

Protocols for management of oral complications of chemotherapy and/or radiotherapy for oral cancer: Systematic review and meta-analysis current

2017

Background and Objectives Considering the high possibility of dentist consult a patient with oral complications of chemotherapy and/or radiotherapy for oral cancer because of the advances in this area, this study aims to systematically review the literature to identify and suggest effective and safe protocols for the managements of oral complications in oncology patients. Material and Methods TThe systematic review was designed by PICO and PRISMA including eligibility and exclusion criteria; the source of information and search strategy in PubMed according MeSH: “Mouth Neoplasms and Radiotherapy” and “Mouth Neoplasms and Drug Therapy” the period from 2010 to 2015; selection and data collect…

medicine.medical_specialtyMEDLINEDentistryAntineoplastic AgentsReview03 medical and health sciences0302 clinical medicinePharmacotherapyClinical ProtocolsmedicineMucositisHumansRadiation InjuriesIntensive care medicineGeneral DentistryMouth neoplasmOral Medicine and PathologyRadiotherapybusiness.industryChlorhexidine030206 dentistryOdds ratio:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseOtorhinolaryngology030220 oncology & carcinogenesisMeta-analysisRelative riskUNESCO::CIENCIAS MÉDICASMouth NeoplasmsSurgeryMouth DiseasesbusinessSystematic Reviews as Topicmedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Prevention and management of musculoskeletal pain in nursing staff by a multifaceted intervention in the workplace: design of a cluster randomized co…

2018

Musculoskeletal pain (MSP) is the leading cause of years lived with disability. In consequence, to reduce MSP and its associated sickness absence is a major challenge. Previous interventions have been developed to reduce MSP and improve return to work of workers with MSP, but combined approaches and exhaustive evaluation are needed. The objective of the INTEVAL_Spain project is to evaluate the effectiveness of a multifaceted intervention in the workplace to prevent and manage MSP in nursing staff. The study is designed as a two-armed cluster randomized controlled trial with a late intervention control group. The hospital units are the clusters of randomization and participants are nurses an…

medicine.medical_specialtyMultifaceted interventionReturn to workCost-Benefit AnalysisMusculoskeletal painPsychological intervention030209 endocrinology & metabolismContext (language use)Nursing Staff HospitalCluster randomized controlled triallaw.inventionCase management03 medical and health sciencesStudy Protocol0302 clinical medicineRandomized controlled triallawIntervention (counseling)Surveys and QuestionnairesSick leavemedicineHumans030212 general & internal medicineOccupational Healthbusiness.industryPublic healthlcsh:Public aspects of medicinePublic Health Environmental and Occupational Healthlcsh:RA1-1270Participatory ergonomicsHealth promotionResearch DesignSpainFamily medicineEconomic evaluationHealth promotionErgonomicsbusinessFollow-Up StudiesBMC public health
researchProduct

Two consecutive clinical trials on cisplatin (CDDP), hepatic arterial infusion (HAI), and I.V. 5-fluorouracil (5-FU) chemotherapy for unresectable co…

1991

Several phase III clinical trials demonstrated that hepatic arterial chemotherapy for unresectable colorectal liver metastases is able to provide significantly higher response rates than those obtained by systemic route: in more than 500 patients collected from 6 randomized trials, the median values of objective response rates were 55% after fluoxuridine (FUdR) continuous hepatic arterial infusion (HAI) vs. 18.5% after FUdR or 5-fluorouracil (5-FU) intravenous (i.v.) chemotherapy. Furthermore, the majority of those studies reported that median survival increased in the patient subgroups treated with intrahepatic chemotherapy, even if not always statistically significant [1-6]. Certainly, FU…

medicine.medical_specialtyOrganoplatinum Compoundsmedicine.medical_treatmentPhases of clinical researchRectumGastroenterologyMetastasisHepatic arterial infusionInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intra-ArterialCisplatinChemotherapybusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival RateClinical trialmedicine.anatomical_structureOncologyFluorouracilDrug EvaluationSurgeryFluorouracilColorectal NeoplasmsFloxuridinebusinessmedicine.drugJournal of Surgical Oncology
researchProduct

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A. Okines, M. Verheij, W. Allum, D. Cunningham & A. Cervantes On behalf of the ESMO Guidelines Working Group* GI Clinical Trials Unit, Royal Marsden Hospital, Sutton, UK; Department of Radiation Oncology and Division of Cellular Biochemistry, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Surgery, Royal Marsden Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton, UK; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia, Spain

medicine.medical_specialtyPalliative careTreatment outcomeMeta-Analysis as TopicStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsGastroscopyRadiation oncologyEpidemiologymedicineHumansNeoplasm MetastasisNeoplasm StagingRandomized Controlled Trials as TopicRadiotherapybusiness.industryIncidenceGeneral surgeryPalliative CareCancerHematologymedicine.diseaseCombined Modality TherapySurvival AnalysishumanitiesSurgeryEuropeClinical PracticeTreatment OutcomeOncologyClinical trials unitDiagnosis treatmentChemotherapy AdjuvantbusinessFollow-Up StudiesAnnals of Oncology
researchProduct

"Card sorting" : a tool for research in ethics on treatment decision-making at the end of life in Alzheimer patients with a life threatening complica…

2011

Abstract Background End stage dementia is a particularly difficult aspect of care for patients with Alzheimer's disease and related dementias. In care institutions, caregivers and family are concerned by treatment decision-making for an acute life threatening complication occurring in Alzheimer patients at the end of life. How should the best treatment pathway be decided: to treat or not to treat? Which arguments are used for decision-making? These are mainly ethical questions which are currently difficult to express and investigate. Methods/Design Cross sectional multicentre study of clinical cases involving 67 health centres (university hospitals, general hospitals, local hospitals and ho…

medicine.medical_specialtyPalliative carethreatening complicationPain medicinelcsh:Special situations and conditionseducationAlternative medicine[SDV.CAN]Life Sciences [q-bio]/CancerDisease[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences[SHS.PHIL] Humanities and Social Sciences/PhilosophyStudy Protocol0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancermedicineDementia030212 general & internal medicinePsychiatryIntensive care medicineMedicine(all)business.industrylcsh:RC952-1245[SHS.PHIL]Humanities and Social Sciences/Philosophycard sortingGeneral Medicinedecision-makingmedicine.disease[SDV.ETH] Life Sciences [q-bio]/Ethicsethicshumanities3. Good health[SDV.ETH]Life Sciences [q-bio]/Ethics[ SHS.PHIL ] Humanities and Social Sciences/PhilosophyCard sorting030220 oncology & carcinogenesisAlzheimer[ SDV.ETH ] Life Sciences [q-bio]/EthicsTreatment decision makingbusinessComplication
researchProduct

Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases

1995

The authors describe one case of a rare primitive non-Hodgkin lymphoma of the uterus, and two cases of primary non-Hodgkin lymphoma of the breast. Histologically, the uterine lymphoma, although clinically confined to the uterus, was a diffuse large cell lymphoma, group G according to the Working formulation for Clinical Usage. The two cases of breast lymphoma were a centrocytic-centroblastic and a lymphoplasmocytoid non-Hodgkin lymphoma, respectively. All cases were initally treated with radical surgery plus radiotherapy, but the first patient showed an early recurrence at distant sites, which required systemic cytotoxic chemotherapy. The patient with uterine non-Hodgkin lymphoma received a…

medicine.medical_specialtyPathologyWorking Formulationmedicine.medical_treatmentMammary glandUterusBreast NeoplasmsCHOPimmune system diseaseshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineRadical surgeryChemotherapybusiness.industryLymphoma Non-HodgkinGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyLymphomaRadiation therapymedicine.anatomical_structureOncologyUterine NeoplasmsFemaleSurgeryLymphoma Large B-Cell DiffuseRadiologybusinessEuropean Journal of Surgical Oncology (EJSO)
researchProduct

Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO2 recirculation (HIPEC-CO2) for colorectal cancer peritoneal m…

2021

Peritoneal dissemination from colorectal cancer (CRC) has long been associated with unfavorable prognosis. However, in the last decades, the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was able to obtain up to 30% 5-year survival rate in selected centers. Despite the wide diffusion of CRS and HIPEC, until now, there are no clear recommendations on the drug of choice for HIPEC nor its technique, and safety and efficacy data of HIPEC regimens and techniques are lacking. We performed a retrospective analysis of a prospectively maintained database of 26 CRS and mitomycin C HIPEC with CO2 recirculation (HIPEC-CO2) for CRC peritoneal metastasis…

medicine.medical_specialtyPeritoneal metastasisColorectal cancerMitomycinSettore MED/18 - CHIRURGIA GENERALE2Hyperthermic Intraperitoneal Chemotherapy030230 surgery03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHyperthermiaAdverse effectSurvival ratePeritoneal NeoplasmsRetrospective StudiesCarcinomatosisHIPECbusiness.industryInducedMitomycin CCommon Terminology Criteria for Adverse EventsCytoreduction Surgical ProceduresHyperthermia InducedCarbon DioxidePrognosismedicine.diseaseColorectal cancerCombined Modality TherapyHIPEC-COSurgerySurvival Rate030220 oncology & carcinogenesisPeritoneal metastasisSurgeryHyperthermic intraperitoneal chemotherapyColorectal NeoplasmsbusinessCytoreductive surgeryUpdates in Surgery
researchProduct

A Review of Countermovement and Squat Jump Testing Methods in the Context of Public Health Examination in Adolescence: Reliability and Feasibility of…

2019

Background In the context of a public health physical fitness (PF) examination in adolescence, a countermovement jump (CMJ) and a squat jump (SJ) are two vertical jump (VJ) tests widely used to evaluate lower limb muscle strength and power, respectively. The main criticism of both the CMJ and SJ test is the lack of test standardization. Therefore, the objectives of this review are: (a) to gather information about both jumps; (b) to investigate whether it is possible to identify common procedures referred to in the CMJ and SJ technical execution, and (c) to design standard operating procedures (SOPs) to promote CMJ and SJ standardization in an adolescent population aged 12-18 years. Methods …

medicine.medical_specialtyPhysiologyPhysical fitnessContext (language use)ReviewPhysical strengthlcsh:Physiology03 medical and health sciencesVertical jump0302 clinical medicineCountermovementCMJvertical jumpPhysiology (medical)medicinelcsh:QP1-981business.industrySJpublic health030229 sport sciencesTest (assessment)Systematic reviewstandardized protocolphysical fitneCMJ; SJ; adolescent; physical fitness; public health; standard operating procedure; standardized protocol; vertical jumpadolescentJumpPhysical therapyphysical fitnessbusinessPsychology030217 neurology & neurosurgerystandard operating procedureFrontiers in physiology
researchProduct

Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the…

2022

Abstract Objectives To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC). Patients and methods We performed a retrospective observational study of RAS and BRAF wild-type, vulnerable patients aged ≥70 years with previously untreated mCRC. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results One hundred and eighteen patients were collected from 14 selected Italian centres.…

medicine.medical_specialtyReduced doseColorectal cancerLeucovorinCetuximabNeutropeniaGastroenterologyFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPanitumumabDoublet chemotherapyAnti-EGFRAgedCetuximabMetastatic colorectal cancerRectal Neoplasmsbusiness.industryPanitumumabAnti-EGFRs Doublet chemotherapy Metastatic colorectal cancer Reduced doses Vulnerable older patientsExanthemamedicine.diseaseRashVulnerable older patients.OncologyColonic NeoplasmsFOLFIRIFluorouracilGeriatrics and Gerontologymedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Geriatric Oncology
researchProduct